Schott Pharma AG KGaASHTPY -42.88%64 Altman Z-Score is 3.27 as of Jul. 02, 2026, which is 37% below its 10-year median of 5.16. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 808 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 56.56% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.57 is strong.
Schott Pharma AG KGaA has a Altman Z-Score of 3.27, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Schott Pharma AG KGaA's Altman Z-Score or its related term are showing as below:
SHTPY'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.05 Med: 5.16 Max: 7.26
Current: 3.57
During the past 6 years, Schott Pharma AG KGaA's highest Altman Z-Score was 7.26. The lowest was 3.05. And the median was 5.16.
Schott Pharma AG KGaA (OTCPK:SHTPY) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Schott Pharma AG KGaA Altman Z-Score Related Terms
Schott Pharma AG KGaA Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHTPY vs ISRG, BDX, MDLN: Altman Z-Score Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Schott Pharma AG KGaA (SHTPY) has a Altman Z-Score of 3.27 as of Jul. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Schott Pharma AG KGaA and its competitors. This is 37% below median its historical median of 5.16. Over the past decade, Schott Pharma AG KGaA's Altman Z-Score has ranged from 3.05 to 7.26. According to the industry distribution chart, Schott Pharma AG KGaA ranks #351 out of 808 companies in the Medical Devices & Instruments industry, placing it in the top 43.4%.
Is Schott Pharma AG KGaA's Altman Z-Score too high?
Schott Pharma AG KGaA's current Altman Z-Score of 3.27 is 37% below median its 10-year median of 5.16. Over the past 10 years, this metric has ranged from a low of 3.05 to a high of 7.26. The Medical Devices & Instruments industry median Altman Z-Score is 2.89. Schott Pharma AG KGaA's value of 3.27 is 13.3% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #351 out of 808 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Altman Z-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #351 out of 808 companies for Altman Z-Score. This puts Schott Pharma AG KGaA in the upper half of its industry. The industry median Altman Z-Score is 2.89. Schott Pharma AG KGaA's value of 3.27 is 13.3% above this benchmark. Historically, Schott Pharma AG KGaA's own Altman Z-Score has ranged from 3.05 to 7.26 over the past decade. While the company's 10-year median is 5.16 vs. the industry median of 2.89, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 2.89, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Altman Z-Score of 3.27 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Altman Z-Score is 3.27, which is 37% below median its own 10-year median of 5.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current Altman Z-Score of 3.27. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current Altman Z-Score is 3.27, which is 37% below median its 10-year median of 5.16 and 13.3% above the Medical Devices & Instruments industry median of 2.89. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current Altman Z-Score is 3.27 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
Altman Z-Score: 3.27 (37% below median its 10-year median of 5.16)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 13.3% above the Medical Devices & Instruments median (#351 of 808)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
